Can a simple pill stop a hidden virus after cancer cell therapy?
NCT ID NCT06575374
First seen Jan 26, 2026 · Last updated Apr 30, 2026 · Updated 19 times
Summary
This study tests whether the drug letermovir can safely prevent the reactivation of cytomegalovirus (CMV) in people who have received a type of cell therapy called axicabtagene ciloleucel. About 36 adults who are CMV-positive and scheduled for this cell therapy will take letermovir and be monitored for side effects and virus activity. The goal is to see if this approach can reduce the risk of CMV-related complications.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CELL THERAPY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.